ClinicalTrials.gg
CompletedNCT04812444Updated Oct 23, 2023

Peripheral Venous Stent System in the Treatment of Iliac Vein Stenosis or Occlusion

An interventional study of Zylox Peripheral Venous Stent and Zilver Vena Venous Stent in Iliac Vein Stenosis and Iliac Vein Occlusion, sponsored by Zhejiang Zylox Medical Device Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Zhejiang Zylox Medical Device Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.

Enrollment
18th of 56
220 · median 145
Started
2020
with 3 others
No phase
48 of 81
21 open now
Registered
27th of 81
by date

Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 18th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2020, is one of 48 with no phase, and was the 27th registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Constriction, Pathologic with a site in China, or all of them as a file.
02

Study summary

Clinical study on safety and efficacy of Zylox peripheral venous stent system in the treatment of iliac vein stenosis or occlusion.

Read the detailed description

The purpose of this study was to evaluate the safety and efficacy of Zylox peripheral venous stent system in the treatment of iliac vein stenosis or occlusive lesions compare with conventional venous stent.

03

Conditions studied

  • Iliac Vein Stenosis
  • Iliac Vein Occlusion

Keywords

  • Peripheral venous stent system
  • Iliac vein patency rate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged from 18 to 75 years old, male or female
  • Subject's target lesions were stenosis and/or occlusion
  • CEAP≥C3
  • Subjects were able to understand the purpose of the study, demonstrate full compliance with the program and sign

Exclusion criteria

Exclusion Criteria:

  • Pregnant woman or who's pregnancy test is positive
  • Lactation period woman or woman/man with fertility plan
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Zylox Peripheral Venous Stent Implantation

    Percutaneous stent placement in the iliofemoral veins

    Device: Zylox Peripheral Venous Stent

  • Active comparator
    Zilver Vena Venous Stent Implantation

    Percutaneous stent placement in the iliofemoral veins

    Device: Zilver Vena Venous Stent

Interventions

  • DeviceZylox Peripheral Venous Stent

    Self-expanding stent implantation during the index procedure.

  • DeviceZilver Vena Venous Stent

    Self-expanding stent implantation during the index procedure.

06

What researchers measure

Primary outcomes

  1. Target vascular patency rate at 12 months after operation

    Target vascular patency rate

    Time frame: 12 months

Secondary outcomes

  1. The incidence of major adverse events

    Related to death of clinical trials

    Time frame: 12 months

  2. Adverse Event

    Adverse medical events,whether or not related to the medical device

    Time frame: Preoperative、Intraoperative、up to 1 month、3 month、6 month、12 month、2 years、3 years、5 years

07

Study locations

1 site
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Oct 2023, 36 months.

Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's 36 months is close to that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2020
First posted
Mar 23, 2021
StartActual
Oct 9, 2020
Primary completionActual
Oct 20, 2023
CompletionActual
Oct 20, 2023
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04812444
Lead sponsor
Zhejiang Zylox Medical Device Co., Ltd.
Responsible party
Sponsor
First posted
Mar 23, 2021
Start date
Oct 9, 2020
Primary completion
Oct 20, 2023
Completion
Oct 20, 2023
Last update
Oct 23, 2023

Study contacts

Yu Zhao
principal investigator · First Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion